Modern Chinese Medicine Group Co., Ltd. (HKG:1643)
Hong Kong · Delayed Price · Currency is HKD 0.6150
-0.0850 (-12.14%)
Oct 8, 2026, 11:18 AM HKT
HKG:1643 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 443 | 367 | 225 | 204 | 330 | 492 | |
Market Cap Growth | -16.89% | 63.20% | 10.29% | -38.18% | -32.93% | - |
Enterprise Value | 306 | 57 | -40 | -100 | 70 | 283 |
Last Close Price | 0.70 | 0.51 | 0.38 | 0.34 | 0.55 | 0.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 21.87 | 3.80 | 3.32 | 4.90 |
PS Ratio | 2.19 | 2.27 | 0.99 | 0.54 | 0.73 | 1.11 |
PB Ratio | 0.93 | 0.66 | 0.44 | 0.39 | 0.69 | 1.19 |
P/TBV Ratio | 0.96 | 0.66 | 0.44 | 0.39 | 0.69 | 1.19 |
P/FCF Ratio | - | - | - | 54.82 | 2.56 | - |
P/OCF Ratio | - | 77.21 | 3.59 | 21.85 | 2.32 | 6.96 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.60 | 0.35 | - | - | 0.16 | 0.64 |
EV/EBITDA Ratio | - | - | - | - | 0.46 | 1.99 |
EV/EBIT Ratio | - | - | - | - | 0.48 | 2.03 |
EV/FCF Ratio | - | - | - | - | 0.55 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0 | 0 | 0 | 0.00 | 0.00 |
Debt / EBITDA Ratio | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / FCF Ratio | - | - | - | 0.02 | 0.00 | - |
Net Debt / Equity Ratio | -0.25 | -0.46 | -0.47 | -0.60 | -0.67 | -0.52 |
Net Debt / EBITDA Ratio | 2.88 | 44.86 | -6.98 | -3.85 | -2.10 | -1.52 |
Net Debt / FCF Ratio | 0.92 | 12.95 | 4.15 | -84.72 | -2.47 | 14.19 |
Asset Turnover | 0.39 | 0.27 | 0.40 | 0.67 | 0.89 | 1.19 |
Inventory Turnover | 4.97 | 4.09 | 4.13 | 5.45 | 4.57 | 4.37 |
Quick Ratio | 7.25 | 7.50 | 6.52 | 7.96 | 4.91 | 4.23 |
Current Ratio | 9.12 | 8.54 | 7.20 | 8.93 | 5.49 | 5.24 |
Return on Equity (ROE) | -8.79% | -2.76% | 2.02% | 10.89% | 23.10% | 34.64% |
Return on Assets (ROA) | -6.50% | -1.91% | 2.79% | 8.30% | 17.98% | 23.47% |
Return on Invested Capital (ROIC) | -15.33% | -6.33% | 7.05% | 29.80% | 60.25% | 71.10% |
Return on Capital Employed (ROCE) | -11.30% | -3.30% | 4.80% | 14.30% | 30.10% | 33.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -9.60% | -4.11% | 4.57% | 26.35% | 30.09% | 20.40% |
FCF Yield | -29.49% | -5.37% | -26.16% | 1.82% | 39.07% | -3.09% |
Dividend Yield | - | - | - | - | - | 2.10% |
Payout Ratio | - | - | - | - | 9.47% | - |
Buyback Yield / Dilution | -20.03% | -10.03% | - | - | -1.04% | -31.96% |
Total Shareholder Return | -20.03% | -10.03% | - | - | -1.04% | -29.87% |